3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
6
Lymphoma
4
Hematologic Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Multiple Myeloma
3
Leukemia, Myeloid, Acute
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia
3
Neoplasm, Residual
2
Lymphoma, Non-Hodgkin
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Osteosarcoma
1
Neurotoxicity Syndromes
1
Neuroblastoma
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma, B-Cell
1
Lymphohistiocytosis, Hemophagocytic
1
Lymphatic Diseases
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Interventions
dacetuzumab
4
tetulomab tetraxetan lu-177
2
Rituximab
2
Lutetium
2
Gemcitabine
2
vandetanib
1
tirbanibulin
1
phenethyl isothiocyanate
1
motesanib diphosphate
1
imetelstat
1
fludarabine
1
ficlatuzumab
1
denileukin diftitox
1
beta-Glucans
1
Nivolumab
1
Lutetium-177
1
Lenalidomide
1
Immunoenzyme Techniques
1
Ganciclovir
1
Erlotinib Hydrochloride
1
Dexamethasone
1
Clofarabine
1
Calcium Dobesilate
1
Bortezomib
1
Bevacizumab
1
Bendamustine Hydrochloride
1
AP 1903 reagent
1
4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphoproliferative Disorders
×
AP 1903 reagent
×
Clear all
NCT01494103
2025-07-11
DOTTI
Baylor College of Medicine
Phase 1
Active not recruiting
15 enrolled